Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2025

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI®
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
IQVIA Careers
Featured Careers
Stay Connected

WE'RE HIRING

"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.

VIEW ROLES
MAIN/Contact Us
Contact Us/
Article
Key Tailwinds and Headwinds Impacting the Outlook for the Asian Pharmaceutical Market
IQVIA Market Prognosis
May 08, 2025
  • Library
  • Key Tailwinds and Headwinds Impacting the Outlook for the Asian Pharmaceutical Market

Get instant access

Download

This article reviews the latest pharmaceutical forecasts from IQVIA's Market Prognosis in the Asia region and presents a summary of key tailwinds and headwinds impacting the region's pharmaceutical market outlook over the next five years. The analysis is based on findings from 12 key Asian markets covered in the March 2025 edition of IQVIA's Market Prognosis, including China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.

Pharmaceutical sales in the 12 Asian markets are forecast to grow at a CAGR of 3.7% between 2024 and 2029, marginally faster than in the previous five years. China, Japan, and India are the largest markets and major contributors to the region's pharmaceutical expansion, together accounting for 81.1% of regional sales in 2024. China, the largest market, is anticipated to expand at a CAGR of 2.8% over 2024–2029, whereas Japan and India, the second and third largest markets, are expected to post a CAGR of 1.2% and 8.0%, respectively. Of the 12 Asian markets, Malaysia will record the fastest growth, posting a CAGR of 8.9% over 2024–2029.

Tailwinds

Increasing demand from a rapidly aging society

Asian markets are experiencing one of the fastest demographic shifts in the world, with their population aging at an unprecedented pace. Countries such as China, Japan, Singapore, South Korea, Taiwan, and Thailand are the vanguard of this trend. The most significant implication of this shift is the growing healthcare and pharmaceutical demand from the elderly population. According to the Economist Intelligence Unit (EIU), the population aged 65+ years in the 12 Asian markets is expected to increase from 409.0 million in 2024 to 514.2 million in 2029, posting a CAGR of 4.7%. As the growth in this cohort accelerates, the need for accessible, affordable, and quality healthcare services is skyrocketing. Long-term care services, including homebased and community-based care are being expanded in Japan, Singapore, South Korea, and Taiwan. However, meeting these needs requires significant public and private investment. Initiatives to increase funding for elderly care are also underway in these countries. For example, the Japanese government has approved around ¥38.3 trillion for FY2025 social security spending. Health ministries in South Korea and Taiwan are planning to launch home-based care services.

Recent and future drug launches driving stronger market growth

Recent and future innovative new products, many addressing unmet medical needs, will drive growth in the Asian pharmaceutical markets. Specialty, orphan, biologic, and oncology products will constitute a growing share of these drugs, leading to a gradual increase in the average price per standard unit and driving growth in value terms. New, more efficacious anti-obesity drugs available on an out-of-pocket basis will also contribute to market growth across the larger Asian markets, especially in China, India, and South Korea.

Facilitating access to innovative drugs

Governments in the Asian markets are implementing strategies to ensure timely access to innovative new drugs for patients. These strategies include streamlining approval processes, expanding reimbursement coverage, and fostering domestic pharmaceutical innovation. China has implemented accelerated regulatory pathways such as priority and conditional approvals to expedite access to innovative drugs. Moreover, the institutionalization of national price negotiation enables the timely inclusion of innovative drugs in the National Reimbursement Drug List, benefiting new drugs for oncology, rare, and other chronic diseases.

To explore the full details of the pharmaceutical forecasts for other Asian countries, along with comprehensive insights into the tailwinds, headwinds, and market outlook, download the complete article.  It offers valuable insights into market dynamics, helping you to anticipate changes, identify opportunities, and strategize effectively in the evolving pharmaceutical landscape.

Related solutions

Market Prognosis

Accelerate strategic decision making with a clear view on future market dynamics, now powered by AI

Contact Us